Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.686 +0.126 (+8.10%)

Delayed Quote Updated: 12:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

May 03, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq

April 26, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conference

April 21, 2023

From Innate Pharma SA

Via Business Wire

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023

April 18, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023

April 07, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F

April 06, 2023

From Innate Pharma SA

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

April 03, 2023

From Innate Pharma SA

Via Business Wire

Earnings Scheduled For March 23, 2023 ↗

March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Via Benzinga

Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update

March 23, 2023

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023

March 20, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results

March 16, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Provides Update on Silicon Valley Bank Exposure

March 13, 2023

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023

February 21, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

February 07, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers

January 25, 2023

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

January 16, 2023

From Innate Pharma SA

Via Business Wire

Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session ↗

December 27, 2022

Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.

Via Benzinga

US Stocks Open Lower; Nasdaq Slides Over 100 Points ↗

December 27, 2022

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 27, 2022

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 19, 2022

Via Benzinga

After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs ↗

December 19, 2022

Via Benzinga

Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket ↗

December 19, 2022

Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in...

Via Benzinga

Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology

December 19, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer ↗

December 12, 2022

Via Benzinga

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

December 10, 2022

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022

December 09, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

December 01, 2022

From Innate Pharma SA

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.